within Pharmacolibrary.Drugs.ATC.L;

model L04AG06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 12 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0040999999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0025,
    k12             = 0.19,
    k21             = 0.19
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AG06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Alemtuzumab is a humanized monoclonal antibody directed against CD52, a protein present on the surface of mature lymphocytes, and is primarily used as an immunosuppressive agent in multiple sclerosis and previously in B-cell chronic lymphocytic leukemia (CLL). Its main purpose is to reduce relapse rates in relapsing forms of multiple sclerosis. It is an approved drug for use in several countries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in patients with relapsing multiple sclerosis receiving intravenous alemtuzumab infusions.</p><h4>References</h4><ol><li><p>Frampton, JE, &amp; Wagstaff, AJ (2003). Alemtuzumab. <i>Drugs</i> 63(12) 1229–1246. DOI:<a href=\"https://doi.org/10.2165/00003495-200363120-00003\">10.2165/00003495-200363120-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12790693/\">https://pubmed.ncbi.nlm.nih.gov/12790693</a></p></li><li><p>Admiraal, R, et al., &amp; Bredius, RGM (2019). Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. <i>Clinical pharmacokinetics</i> 58(12) 1609–1620. DOI:<a href=\"https://doi.org/10.1007/s40262-019-00782-0\">10.1007/s40262-019-00782-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31131436/\">https://pubmed.ncbi.nlm.nih.gov/31131436</a></p></li><li><p>Loeff, FC, et al., &amp; Halkes, CJM (2019). Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft. <i>Transplant immunology</i> 57 101209–None. DOI:<a href=\"https://doi.org/10.1016/j.trim.2019.06.001\">10.1016/j.trim.2019.06.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31207283/\">https://pubmed.ncbi.nlm.nih.gov/31207283</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AG06;
